Lumida
/MAZE
⌘K
Maze Therapeutics Inc

Maze Therapeutics Inc

MAZE
$28.12USD+3.52%+0.96 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$27 – $28

52W RANGE

$13
$54

AI Summary

Stalk
StalkMedium

We are in a Stage 2 advancing environment with a strong Lockout Rally driving upside urgency. The medium-term directional asymmetry remains bullish supported by the advancing Market Stage and continuation pattern. Short-term price is extended and overbought and is pulling back into rising EMAs, making immediate buy conditions unfavorable. We will defer entry and watch for a pullback to absorb into the 9/21/50 EMA support zone before engaging.

  • Phase 2 HORIZON trial delivered 36% mean uACR reduction (>30% POC)
  • $362.9 M cash funds operations into 2029
  • Earnings yield negative at –2.6%, reflecting ongoing losses
Full analysis →
Insider Trades29 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 1, 2026SellMAZEHarold BernsteinPresident, R&D & CMO29,218$20.16$1.6B-47.59%+119.52%$589.1K+0.00%10b5-1Stalk
Jul 1, 2026SellMAZEJason V ColomaChief Executive Officer34,501$29.98$1.6B-47.59%+119.52%$1.0M-5.44%10b5-1Stalk
Jun 29, 2026SellMAZEAtul DandekarCSBO15,000$19.22$1.6B-47.59%+119.52%$288.3K+0.00%10b5-1Stalk
Jun 22, 2026SellMAZEJason V ColomaChief Executive Officer27,858$26.04$1.6B-47.59%+119.52%$725.5K-3.89%10b5-1Stalk
Jun 1, 2026SellMAZEJason V ColomaChief Executive Officer6,643$26.20$1.6B-47.59%+119.52%$174.0K-1.75%10b5-1Stalk
Jun 1, 2026SellMAZEHarold BernsteinPresident, R&D & CMO29,706$18.04$1.6B-47.59%+119.52%$535.9K+0.00%10b5-1Stalk
May 29, 2026SellMAZEAtul DandekarCSBO15,000$18.38$1.6B-47.59%+119.52%$275.7K+0.00%10b5-1Stalk
May 22, 2026SellMAZEJason V ColomaChief Executive Officer32,564$26.01$1.6B-47.59%+119.52%$847.0K-4.13%10b5-1Stalk
May 15, 2026SellMAZEJason V ColomaChief Executive Officer1,938$26.00$1.6B-47.59%+119.52%$50.4K-0.47%10b5-1Stalk
May 14, 2026SellMAZEHarold BernsteinPresident, R&D & CMO30,000$18.32$1.6B-47.59%+119.52%$549.7K+0.00%10b5-1Stalk
May 4, 2026BuyMAZEAtul DandekarCSBO14,305$10.42$1.6B-47.59%+119.52%$149.1K+18.52%Stalk
Apr 29, 2026SellMAZEAtul DandekarCSBO15,000$17.90$1.6B-47.59%+119.52%$268.4K+0.00%10b5-1Stalk
Apr 1, 2026SellMAZEAmy BachrodtSVP, Finance5,000$19.93$1.6B-47.59%+119.52%$99.7K+0.00%10b5-1Stalk
Apr 1, 2026SellMAZEHarold BernsteinPresident, R&D & CMO30,000$19.94$1.6B-47.59%+119.52%$598.2K+0.00%10b5-1Stalk
Mar 30, 2026SellMAZEAtul DandekarCSBO15,000$19.88$1.6B-47.59%+119.52%$298.2K+0.00%10b5-1Stalk
Mar 20, 2026SellMAZEHarold BernsteinPresident, R&D & CMO30,000$29.76$1.6B-47.59%+119.52%$892.7K+0.00%10b5-1Stalk
Mar 10, 2026SellMAZEHarold BernsteinPresident, R&D & CMO60,000$30.44$1.6B-47.59%+119.52%$1.8M+0.00%10b5-1Stalk
Mar 2, 2026SellMAZEAmy BachrodtSVP, Finance10,000$27.81$1.6B-47.59%+119.52%$278.1K+0.00%10b5-1Stalk
Feb 27, 2026SellMAZEAtul DandekarCSBO15,000$27.92$1.6B-47.59%+119.52%$418.9K+0.00%10b5-1Stalk
Feb 2, 2026SellMAZEAmy BachrodtSVP, Finance10,000$28.23$1.6B-47.59%+119.52%$282.3K+0.00%10b5-1Stalk
Feb 2, 2026SellMAZEHarold BernsteinPresident, R&D & CMO30,000$28.22$1.6B-47.59%+119.52%$846.6K+0.00%10b5-1Stalk
Jan 29, 2026SellMAZEAtul DandekarCSBO15,000$27.34$1.6B-47.59%+119.52%$410.1K+0.00%10b5-1Stalk
Jan 22, 2026SellMAZEAmy BachrodtSVP, Finance10,000$27.97$1.6B-47.59%+119.52%$279.7K+0.00%10b5-1Stalk
Jan 7, 2026SellMAZEHarold BernsteinPresident, R&D & CMO50,312$25.31$1.6B-47.59%+119.52%$1.3M+0.00%10b5-1Stalk
Jan 2, 2026SellMAZEHarold BernsteinPresident, R&D & CMO9,688$25.41$1.6B-47.59%+119.52%$246.1K+0.00%10b5-1Stalk
Jan 2, 2026SellMAZEAmy BachrodtSVP, Finance10,000$24.79$1.6B-47.59%+119.52%$247.9K+0.00%10b5-1Stalk
Dec 29, 2025SellMAZEAmy BachrodtSVP, Finance30,000$25.42$1.6B-47.59%+119.52%$762.5K+0.00%10b5-1Stalk
Dec 29, 2025SellMAZEHarold BernsteinPresident, R&D & CMO90,000$25.49$1.6B-47.59%+119.52%$2.3M+0.00%10b5-1Stalk
Dec 29, 2025SellMAZEAtul DandekarCSBO145,000$25.49$1.6B-47.59%+119.52%$3.7M+0.00%10b5-1Stalk